LOVAZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOVAZA (LOVAZA).
Lovaza (omega-3-acid ethyl esters) reduces hepatic very low-density lipoprotein (VLDL) synthesis and triglyceride levels by decreasing the production of apolipoprotein B-100 and increasing the clearance of triglycerides from circulating VLDL particles.
| Metabolism | Hydrolyzed by pancreatic lipases to free fatty acids; further metabolized via beta-oxidation; not subject to CYP450 metabolism. |
| Excretion | Primarily fecal as unchanged drug (≥90%), with renal excretion of metabolites <5%. |
| Half-life | Terminal half-life of EPA is approximately 7–8 hours; DHA half-life is approximately 30 hours. Clinically, steady state is achieved within 1–2 weeks. |
| Protein binding | Highly bound (>99%) primarily to albumin. |
| Volume of Distribution | Approximately 0.1–0.2 L/kg, indicating limited extravascular distribution and confinement to plasma volume. |
| Bioavailability | Oral bioavailability of omega-3-acid ethyl esters is approximately 20–30% when taken with a low-fat meal; absorption increases 2–3 fold with a high-fat meal. |
| Onset of Action | Oral: Reductions in serum triglycerides are observed within 2–4 weeks of daily dosing. |
| Duration of Action | Triglyceride-lowering effect persists as long as therapy continues; effects decline within weeks of discontinuation. |
4 g/day orally (as 4 capsules of 1 g each, taken as 2 capsules twice daily or 4 capsules once daily) with meals.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (CrCl <30 mL/min) or ESRD; use with caution. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years of age. |
| Geriatric use | No specific dose adjustment recommended; studies included patients up to 89 years; use standard adult dosing with monitoring for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOVAZA (LOVAZA).
| Breastfeeding | Not recommended during breastfeeding. Omega-3-acid ethyl esters are excreted in human milk in small amounts; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. Omega-3-acid ethyl esters (LOVAZA) cross the placenta. In animal studies, increased fetal death, delayed parturition, and increased incidence of stillbirths were observed at high doses. Risk to fetus cannot be ruled out; use only if potential benefit justifies potential risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component of the product"]
| Precautions | ["May increase LDL-C levels; monitor LDL-C","May prolong bleeding time; use with caution in patients with known hypersensitivity to fish or fish products","Contains ethyl esters of omega-3 fatty acids; may cause allergic reactions","Not shown to prevent cardiovascular events in patients with diabetes or prediabetes"] |
Loading safety data…
| Fetal Monitoring | Monitor triglycerides and lipid panel periodically. For pregnant women, monitor fetal growth and well-being as clinically indicated. No specific fetal monitoring required solely due to LOVAZA; standard obstetric monitoring applies. |
| Fertility Effects | No specific human data on fertility. Animal studies showed no impairment of fertility at therapeutic doses. Theoretical concerns due to omega-3 effects on prostaglandins and reproductive processes; clinical significance unknown. |